Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Acquisitions & Divestments (2016 - 2022)

Historic Change in Acquisitions & Divestments for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Q3 2022 value amounting to $9.9 million.

  • Catalyst Pharmaceuticals' Change in Acquisitions & Divestments changed N/A to $9.9 million in Q3 2022 from the same period last year, while for Dec 2022 it was $9.9 million, marking a year-over-year change of. This contributed to the annual value of $19.2 million for FY2022, which is N/A changed from last year.
  • As of Q3 2022, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments stood at $9.9 million.
  • Catalyst Pharmaceuticals' 5-year Change in Acquisitions & Divestments high stood at $31.7 million for Q4 2019, and its period low was $5.0 million during Q1 2020.
  • Over the past 4 years, Catalyst Pharmaceuticals' median Change in Acquisitions & Divestments value was $10.0 million (recorded in 2019), while the average stood at $14.4 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments soared by 12294.65% in 2019 and then crashed by 7549.02% in 2020.
  • Over the past 4 years, Catalyst Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $14.2 million in 2018, then surged by 122.95% to $31.7 million in 2019, then crashed by 84.21% to $5.0 million in 2020, then soared by 97.36% to $9.9 million in 2022.
  • Its Change in Acquisitions & Divestments was $9.9 million in Q3 2022, compared to $5.0 million in Q1 2020 and $31.7 million in Q4 2019.